|
[23]
|
8
|
Erosive hand OA unresponsive to NSAIDs
|
200 mg HCQ
|
6/8 noted improvement in pain, reduced synovitis and reduced morning stiffness
|
| | | | |
Response time 7/52 to 7/12. No adverse effects
|
|
[24]
|
15
|
Hand OA
|
Placebo-controlled HCQ
|
Improvement in clinical symptoms at 12 months (Ritchie index)
|
|
[25]
|
7
|
Erosive hand OA
|
200 to 400 mg HCG
|
Improvement in 7/7 patients noted
|
|
[26]
|
15
|
Hand and knee OA
|
HCQ 6/12
|
13/15 patients achieved good therapeutic response after 6 months
|
|
[27]
|
29
|
Knee OA
|
400 mg HCQ 4/12, placebo-controlled
|
No difference in WOMAC pain (P = 0.551), stiffness (P = 0.512) or function (P = 0.293); no difference on VAS (P = 0.461) or Lequesne (P = 0.803) scales
|
|
[28]
|
88
|
Nodal OA of the hands
|
HCQ 200 mg/bid, ACM 1.3 gm/tid or placebo 6/12
|
No significant difference between hydroxychloroquine, acetaminophen or placebo in mean number of tender joints at 24 weeks
|
|
[29]
|
8
|
Erosive or inflammatory OA
|
HCQ 200 to 400 mg
|
Clinical improvement in 5/8 patients, 3 patients discontinued (1 due to unresponsiveness, 2 due to side-effects)
|
|
[30]
| | | |
Intra-articular chloroquine in RA and OA of knee joint
|
| | | | |
No abstract available
|
